This review article examined randomized controlled trials investigating methylene blue and its derivatives as potential treatments for Alzheimer’s disease, synthesizing evidence from human clinical trials. The review identified that methylene blue demonstrates some cognitive benefits in Alzheimer’s patients, though results across trials showed variable efficacy and the optimal dosing and formulation remain unclear. Evidence level: Human clinical trials (via systematic review).